stockportfolio.pro
Cerus Corporation (CERS)
Healthcare · Medical Devices · NasdaqGM
Cerus Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.27M | $51.33M | $76.05M | $93.77M | $114.25M | $159.52M | $162.05M | $156.37M | $180.27M | $206.13M |
| Gross profit | $16.89M | $28.80M | $44.42M | $60.35M | $73.09M | — | $87.09M | $86.40M | $99.52M | $112.29M |
| Net income | $-62.91M | $-60.59M | $-57.56M | $-71.24M | $-59.86M | $-54.37M | $-42.78M | $-37.49M | $-20.92M | $-15.63M |
| Net margin | -160.2% | -118.0% | -75.7% | -76.0% | -52.4% | -34.1% | -26.4% | -24.0% | -11.6% | -7.6% |
Source: Cerus Corporation SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into CERS stock?
At today's market cap of $503.93M, Cerus Corporation is priced for free-cash-flow growth of about 52.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.11M from the FY ending 2025-12-31). For comparison, revenue 12.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Cerus Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CERS in your portfolio →
Cerus Corporation financial history by metric
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus Corporation — frequently asked questions
What is Cerus Corporation's revenue?
Cerus Corporation (CERS) reported revenue of $206.13M for fiscal year 2025, up 14.3% from the prior year, according to its SEC filings.
Is Cerus Corporation profitable?
No — CERS reported a net loss of $-15.63M in fiscal 2025.
What is CERS's P/E ratio?
Cerus Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Cerus Corporation growing?
CERS's revenue grew at roughly 12.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Cerus Corporation have?
As of fiscal year 2025, CERS carried roughly $83.89M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cerus Corporation's gross margin?
CERS's gross margin was 54.5% in fiscal 2025 — gross profit of $112.29M on revenue of $206.13M.
What is Cerus Corporation's market cap?
Cerus Corporation (CERS) has a market capitalization of about $503.93M, based on the latest data in our nightly-refreshed cache.
When does Cerus Corporation's fiscal year end?
CERS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CERS stock?
At today's market cap of $503.93M, Cerus Corporation is priced for free-cash-flow growth of about 52.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.11M from the FY ending 2025-12-31). For comparison, revenue 12.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Cerus Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.